Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study

NCT02029378 is registered in ClinicalTrials.gov with NHS Greater Glasgow and Clyde as lead sponsor.

NCT NCT02029378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02029378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study
Lead sponsor
NHS Greater Glasgow and Clyde
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2014
Completion date
March 31, 2016
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gullian barre syndrome